Currently, there are 112.29M common shares owned by the public and among those 108.96M shares have been available to trade.
The company’s stock has a 5-day price change of 13.92% and 33.47% over the past three months. VKTX shares are trading -40.18% year to date (YTD), with the 12-month market performance down to -24.98% lower. It has a 12-month low price of $18.92 and touched a high of $81.73 over the same period. VKTX has an average intraday trading volume of 3.80 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.51%, 10.02%, and -23.55% respectively.
Institutional ownership of Viking Therapeutics Inc (NASDAQ: VKTX) shares accounts for 69.34% of the company’s 112.29M shares outstanding.
It has a market capitalization of $3.39B and a beta (3y monthly) value of 0.66. The earnings-per-share (ttm) stands at -$1.15. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.60% over the week and 6.30% over the month.
Analysts forecast that Viking Therapeutics Inc (VKTX) will achieve an EPS of -0.44 for the current quarter, -0.48 for the next quarter and -2.49 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.55 while analysts give the company a high EPS estimate of -0.55. Comparatively, EPS for the current quarter was -0.2 a year ago. Earnings per share for the fiscal year are expected to decrease by -86.96%, and -35.97% over the next financial year.
Looking at the support for the VKTX, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on April 29, 2025, with the firm’s price target at $104. Goldman coverage for the Viking Therapeutics Inc (VKTX) stock in a research note released on April 08, 2025 offered a Neutral rating with a price target of $30. Scotiabank was of a view on February 13, 2025 that the stock is Sector Outperform, while Citigroup gave the stock Neutral rating on February 07, 2025, issuing a price target of $38. Piper Sandler on their part issued Overweight rating on December 02, 2024.
